BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
49.67
-2.14 (-4.13%)
May 18, 2026, 4:00 PM EDT - Market closed
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,221 employees as of December 31, 2025. The number of employees increased by 181 or 5.95% compared to the previous year.
Employees
3,221
Change (1Y)
181
Growth (1Y)
5.95%
Revenue / Employee
$1,006,618
Profits / Employee
$83,434
Market Cap
9.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,221 | 181 | 5.95% |
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | 3,001 | 152 | 5.34% |
| Dec 31, 2018 | 2,849 | 268 | 10.38% |
| Dec 31, 2017 | 2,581 | 288 | 12.56% |
| Dec 31, 2016 | 2,293 | 135 | 6.26% |
| Dec 31, 2015 | 2,158 | 477 | 28.38% |
| Dec 31, 2014 | 1,681 | 340 | 25.35% |
| Dec 31, 2013 | 1,341 | 252 | 23.14% |
| Dec 31, 2012 | 1,089 | 87 | 8.68% |
| Dec 31, 2011 | 1,002 | 131 | 15.04% |
| Dec 31, 2010 | 871 | 151 | 20.97% |
| Dec 31, 2009 | 720 | 71 | 10.94% |
| Dec 31, 2008 | 649 | 124 | 23.62% |
| Dec 31, 2007 | 525 | 115 | 28.05% |
| Dec 31, 2006 | 410 | 96 | 30.57% |
| Dec 31, 2005 | 314 | -45 | -12.53% |
| Dec 31, 2004 | 359 | 87 | 31.99% |
| Dec 31, 2003 | 272 | 53 | 24.20% |
| Dec 31, 2002 | 219 | 3 | 1.39% |
| Dec 31, 2001 | 216 | 42 | 24.14% |
| Dec 31, 2000 | 174 | 25 | 16.78% |
| Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
BMRN News
- 13 hours ago - BioMarin initiated with a Buy at Citi - TheFly
- 15 hours ago - BioMarin price target lowered to $62 from $64 at Leerink - TheFly
- 19 hours ago - BioMarin price target lowered to $50 from $55 at H.C. Wainwright - TheFly
- 20 hours ago - BioMarin's genetic disease therapy shows mixed results in late-stage study - Reuters
- 20 hours ago - BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial - TheFly
- 21 hours ago - BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency - PRNewsWire
- 8 days ago - BioMarin reinstated with a Neutral at Goldman Sachs - TheFly
- 11 days ago - BioMarin price target raised to $116 from $104 at Canaccord - TheFly